Flubok regulatory update

Astellas submitted an application to Japan's Ministry of Health, Labor and Welfare (MHLW) for ASP7374 to prevent influenza infection. The submission triggered an undisclosed milestone payment to UMN Pharma from Astellas under a 2010 deal in which the companies are co-developing the vaccine in Japan. Protein Sciences will receive a portion of the milestone under an amended 2006 deal granting UMN Pharma rights to the product in Asian countries, such as Japan, China, South Korea, Taiwan, Hong Kong and Singapore (see BioCentury, Nov. 22, 2010). Astellas has exclusive commercialization rights in Japan under its deal with UMN Pharma. ...